Quipt Home Medical Corp. (QIPT Q2 FY2025 earnings call

• Quipt Home Medical is a diversified healthcare services company delivering home medical equipment and services, with over 130 locations across 26 states serving over 223,000 active patients.
• Respiratory care is the core focus, aligning with macro trends like aging population and chronic respiratory conditions.
• Structural efficiencies initiatives began in late 2024, including streamlining back-office functions and optimizing logistics, resulting in an adjusted EBITDA margin of 23.3% despite revenue decline.
• Actively engaging with healthcare systems to create strategic partnerships, focusing on integrated care delivery.
• GLP-1 medications have no impact on sleep business demand; real-world data supports positive effects on treatment adherence and resupply orders.
• Landmark meta-analysis highlights clinical impact of CPAP therapy, reinforcing its value.

Respiratory care is the core focus, compromising approximately 75% of the product mix. Revenue for fiscal Q2 2025 was $57.4 million, down 6% year-over-year. Adjusted EBITDA for Q2 2025 was $13.4 million at 23.3% of revenue. Recurring revenue for Q2 2025 continued to be strong at 81% of total revenue. The company's customer base declined 2% year-over-year, serving 146,000 unique patients as of March 31, 2025. Revenue for the six months ended March 31, 2025, decreased to $118.8 million compared to $123.8 million for the same period in 2024, representing a 4% decrease. Adjusted EBITDA for the six months ended March 31, 2025, was $27.4 million compared to $30.2 million for the same period in 2024, a decrease of 10.4%.

• Trends suggest stabilization and some uptick in rental revenue and supplies business, with positive trends in the right direction.
• Focus on restoring consistent organic growth by leaning into core competencies, clinical respiratory care, and efficient technology-enabled service delivery.
• Active share repurchase program under NCIB to utilize current low valuation.

• Philips recall causing cash constraints and timing issues with equipment recycling, with expectation of over the next couple of quarters for spend to stabilize but timeline extended.
• Impact of Humana capitated contract on referral patterns and revenue.
• Non-renewal of a disposable supply contract contributing to revenue impact.

Q: Can you get a little more color on the two discrete items you guys called out in terms of the revenue impact this quarter, specifically Humana loss of MA members and the disposable supply contract issue?

A: Greg Crawford mentioned it has to do more with referral patterns regarding Humana, underestimated referral impact, and the disposable supply contract was not renewed in fiscal '25 with only one month impact.

Q: Do you think your growth engine can become effective this quarter in terms of looking at a quarter-on-quarter trend?

A: Greg Crawford said trends suggest stabilization and some uptick in rental revenue and recovery on supplies business, with trends in the right direction but just one month into it.

Q: Can you give commentary on cash flow, specifically CapEx spend and cost of inventory sold as a percentage of revenue?

A: Hardik Mehta discussed timing, Philips recall causing cash constraints, and cost of goods stabilizing with year-to-date numbers and expectation of positive trends going into Q3 and Q4.